Press release
Rising Cancer Cases and Technological Innovations Drive Growth in NGS Oncology Market
NGS Oncology Market
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/4575
NGS technologies, including whole-genome sequencing, RNA sequencing, and targeted gene panels, are transforming cancer diagnosis and treatment. These tools allow for precise identification of genetic mutations that drive cancer, helping doctors develop more effective and individualized treatment plans. The growing use of NGS is supported by advances in sequencing methods, cloud-based data storage, and artificial intelligence, which allow for more efficient processing and interpretation of complex genetic data.
The rising demand for precision medicine is also fueling NGS adoption. Tools like liquid biopsies and targeted sequencing are helping doctors detect cancers earlier and monitor how tumors respond to treatment in real time. According to the International Agency for Research on Cancer (IARC), 2024 data shows that there were 20 million new cancer cases and 9.7 million cancer-related deaths globally, with lung and breast cancers being the most prevalent. NGS is proving essential in addressing these challenges by offering insights that improve survival rates.
Market Drivers
The steady increase in cancer cases worldwide is a key factor behind the growth of the NGS oncology market. The National Cancer Institute (NCI) notes that about 40% of people will be diagnosed with cancer during their lifetime. This alarming statistic highlights the need for better diagnostic tools. NGS helps by offering detailed genetic profiling that leads to more accurate diagnoses and tailored treatments.
Market Restraints
Despite its promise, the high cost of NGS remains a significant barrier to wider adoption. Sequencing technologies and the infrastructure needed to support them require major investment. In clinical settings, comprehensive genetic tests can cost several hundred to several thousand dollars per patient. These high costs are particularly challenging for low- and middle-income countries, where access to advanced technology is often limited. This limits the availability of personalized cancer treatment in these regions, widening global health disparities.
Efforts are underway to make NGS more affordable, including investments in cost-reduction strategies, funding support, and the development of more accessible solutions for under-resourced healthcare systems.
Technology Insights
Among the various NGS approaches, targeted sequencing and resequencing are currently leading the market. These methods focus on specific regions of the genome, helping detect important mutations such as BRCA1/BRCA2 in breast cancer and EGFR in lung cancer. Their cost-effectiveness and high accuracy make them suitable for clinical use and compatible with current diagnostic procedures. Targeted sequencing is also widely used in liquid biopsies, which are gaining popularity as non-invasive tools for cancer detection and monitoring.
Whole-genome sequencing (WGS), though more complex and data-intensive, is quickly gaining traction. It provides a complete picture of cancer-related genetic changes, including rare mutations and large genomic alterations. As sequencing costs continue to fall and bioinformatics tools improve, WGS is becoming more accessible for research and clinical use. According to the National Human Genome Research Institute (NHGRI), the cost of sequencing a full human genome dropped from over $4,000 in 2015 to under $1,500, making large-scale genomic analysis more practical than ever.
Request For An Discount@ https://www.emergenresearch.com/request-discount/4575
NGS Oncology Top Companies and Competitive Landscape
The NGS Oncology market is somewhat fragmented, featuring competition between global and regional companies that aim to foster innovation and expand the market. Major firms, such as Illumina Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., BGI Genomics Co. Ltd., Oxford Nanopore Technologies Ltd., Thermo Fisher Scientific, PerkinElmer Inc., and Pacific Biosciences of California, Inc., among others. These firms are utilizing tactics like strategic partnerships, new product introductions, and ongoing technological innovations to strengthen their market standings.
Companies such as Illumina Inc. and Thermo Fisher Scientific emphasize enhancing high-throughput sequencing technologies that are transforming cancer diagnosis and treatment. Firms like Qiagen and Agilent Technologies focus on diagnostic kits and molecular tests, significantly contributing to the incorporation of NGS into clinical oncology.
At the same time, F. Hoffmann-La Roche Ltd. and Oxford Nanopore Technologies are working on incorporating NGS into personalized medicine, enhancing cancer treatment through customized therapeutic strategies. With increasing demand for improved and efficient cancer diagnostics, these companies are intensifying their R&D initiatives, establishing collaborations, and investing heavily in the advancement of next-generation sequencing technologies.
In October 2023, Illumina released the customer release notes for the NovaSeq X Plus Sequencing System Software Suite v1.2.0. This update includes guidance for users on how to share their desktop while collaborating with Technical Support, enhancing the support experience for users of this advanced sequencing platform.
Some of the key companies in the global NGS Oncology Market include:
Illumina Inc.
Thermo Fisher Scientific Inc.
Qiagen N.V.
Agilent Technologies Inc.
F. Hoffmann-La Roche Ltd.
BGI Genomics Co. Ltd.
Oxford Nanopore Technologies Ltd.
Thermo Fisher Scientific
PerkinElmer Inc.
Pacific Biosciences of California, Inc.
Acquire the complete research report on the Global Market@ https://www.emergenresearch.com/industry-report/ngs-oncology-market
NGS Oncology Latest Industry Updates
In January 2024, QIAGEN Digital Insights launched an ultra-fast next-generation sequencing (NGS) analysis tool for somatic cancer, enhancing its QIAGEN CLC Genomics Workbench Premium with LightSpeed technology. This software accelerates the conversion of raw sequencing data into interpretable genetic variant lists at a significantly reduced cost and speed. The solution aims to streamline the analysis process for clinical labs, facilitating quicker insights into cancer genomics.
In May 2023, Pfizer and Thermo Fisher Scientific have partnered to enhance access to next-generation sequencing (NGS) testing for breast and lung cancer patients in over 30 countries across Latin America, Africa, the Middle East, and Asia. This collaboration aims to address the lack of affordable genomic testing in these regions, enabling faster gene analysis that helps healthcare providers tailor treatments to individual patients.
NGS Oncology Market Segmentation Analysis
By Offering Outlook (Revenue, USD Billion; 2020-2033)
Products
Instruments
Consumables
Sample Preparation Consumables
DNA Extraction and Amplification
Library Preparation and Target Enrichment
Quality Control
Other Consumables
Software
Services
Sequencing Services
Data Analysis Services
By Technology Outlook (Revenue, USD Billion; 2020-2033)
Targeted Sequencing & Resequencing
Amplicon-based
Hybridization-based
Whole Genome Sequencing
Whole Exome Sequencing
By Application Outlook (Revenue, USD Billion; 2020-2033)
Diagnostics
Drug Discovery and Development
Personalized Medicine
Biomarker Discovery
Others
By Workflow Outlook (Revenue, USD Billion; 2020-2033)
Pre-sequencing
Sequencing
Data Analysis
By End User Outlook (Revenue, USD Billion; 2020-2033)
Hospitals and Clinics
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
Others
By Regional Outlook (Revenue, USD Billion; 2020-2033)
North America
United States
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Benelux
Rest of Europe
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America
Brazil
Rest of Latin America
Middle East and Africa
Saudi Arabia
UAE
South Africa
Turkey
Rest of MEA
Buy Now@ https://www.emergenresearch.com/select-license/4575
Explore Similar Reports offered by Emergen Research:
NGS Oncology Market Size@ https://www.emergenresearch.com/industry-report/ngs-oncology-market/market-size
NGS Oncology Market Share@ https://www.emergenresearch.com/industry-report/ngs-oncology-market/market-share
NGS Oncology Market Trends@ https://www.emergenresearch.com/industry-report/ngs-oncology-market/market-trends
NGS Oncology Regional Market Demand@ https://www.emergenresearch.com/industry-report/ngs-oncology-market/regional-market-demand
NGS Oncology Market Analysis@ https://www.emergenresearch.com/industry-report/ngs-oncology-market/market-analysis
Contact Us:
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Cancer Cases and Technological Innovations Drive Growth in NGS Oncology Market here
News-ID: 4014646 • Views: …
More Releases from Emergen Research
Global Internet of Things (IoT) in Healthcare Market to Reach USD 299.05 Billion …
The global Internet of Things (IoT) in Healthcare Market was valued at USD 299.05 billion in 2023 and is expected to grow at a CAGR of 16.5% during the forecast period. This growth is fueled by the rising use of connected healthcare devices, increasing demand for early disease detection through remote monitoring, and growing adoption of artificial intelligence (AI) tools within IoT-based healthcare systems.
The market is also benefiting from the…
Global Stem Cell Therapy Market to Reach USD 49.2 Billion by 2034, Growing at 13 …
The global Stem Cell Therapy Market, valued at USD 13.7 billion in 2024, is projected to reach USD 49.2 billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.6%. Growth is being fueled by the rising burden of chronic diseases, rapid progress in cell-based studies, and increasing investments in regenerative medicine and personalized healthcare solutions.
Stem cell therapies offer the ability to repair, replace, or restore damaged tissues…
Artificial Intelligence Strengthens Cybersecurity as Threats Grow More Sophistic …
The global Artificial Intelligence in cybersecurity market size was USD 23.8 Billion in 2023 and is expected to reach a market valuation of USD 29.44 billion by the end of 2024 registering a CAGR of 23.7% during the forecast period. The adoption of Artificial Intelligence (AI) in cybersecurity is rapidly gaining traction as organizations worldwide face increasingly complex and frequent cyber threats. By combining advanced technologies such as Machine Learning…
Global Regenerative Medicine Market to Reach USD 125.6 Billion by 2034, Growing …
The global regenerative medicine market, valued at USD 34.2 billion in 2024, is set to grow to USD 125.6 billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.9%. Growth is being fueled by rising approvals of advanced therapies, strong demand for personalized treatments in cancer and orthopedics, and expanding cell and gene therapy manufacturing across major markets such as North America, Europe, and Asia.
Once seen as…
More Releases for NGS
Next Generation Sequencing (NGS) : - Key Industry Dynamics
The Next Generation Sequencing (NGS) market size is projected to reach US$ 34.75 billion by 2031 from US$ 10.00 billion in 2023. The market is expected to register a CAGR of 16.8% during 2023-2031. Increased throughput and reduced costs is likely to remain key trends in the market.
Next-generation sequencing (NGS) carries a shift in genomics research, offering unmatched capabilities for analyzing DNA and RNA molecules in a high-throughput and cost-effective…
Next-Generation Sequencing (NGS) Services Next-Generation Sequencing (NGS) Servi …
Global Next-Generation Sequencing (NGS) Services Market Report encompasses market data, such as trends, consumer behavior, and competitive analysis in a way that allows businesses to identify opportunities in the market. The objective of the market research is understood very clearly by DBMR team before the creation of report commences. Intense research takes place to accurately analyze market dynamics and consumer behaviour included in the report.
Global Next-Generation Sequencing (NGS) Services Market,…
Complete PDF Guide to NGS Sample Preparation
The NGS sample preparations determine components in the samples, such as blood, urine, and others, in animals.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 @ https://www.theinsightpartners.com/sample/TIPRE00006573?utm_source=OpenPR&utm_medium=10379
The type of analyzers includes urine analyzers, blood gas & electrolyte analyzers, glucometers, and others used by medical labs, hospitals, and people at home.
Top Companies Analysis -
Agilent Technologies, Inc.
Becton, Dickinson and Company
Beckman Coulter
F. Hoffmann-La Roche AG
Illumina, Inc.
…
NGS Sample Preparation Market - Preparing for Precision: NGS Sample Preparation …
Newark, New Castle, USA: The "NGS Sample Preparation Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
NGS Sample Preparation Market: https://www.growthplusreports.com/report/ngs-sample-preparation-market/8504
This latest report researches the industry structure,…
NGS Library Preparation Market - Sequencing Solutions, Redefined: Innovations in …
Newark, New Castle, USA - new report, titled NGS Library Preparation Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the NGS Library Preparation market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global NGS Library Preparation market. The report offers an overview of…
Next Generation Sequencing (NGS) Data Analysis Market Research Report 2020Next G …
The Next Generation Sequencing (NGS) Data Analysis Market report helps identify the biggest opportunities in Next Generation Sequencing (NGS) Data Analysis industry space and offers accurate latent demand forecasting that empowers quantitative decision making among Next Generation Sequencing (NGS) Data Analysis market players and new entrants. Investors will gain a clear insight on the dominant players in Next Generation Sequencing (NGS) Data Analysis industry and their future forecasts. Furthermore, readers…
